Evaluation of CADstreamTM for serial automated breast tumor volume measurements in patients undergoing neoadjuvant chemotherapy for breast cancer
Urioste A, Joe B, Vahidi K, Gibbs J, Lu Y, Hylton N, Siraj Z, Proctor E
University of California, San Diego
MRI breast tumor volume has recently been shown to be predictive of length of recurrence free survival (LRFS) in breast cancer patients undergoing neoadjuvant chemotherapy. This study evaluates a software package (CADstreamTM, Confirma, Inc.) for automated measurement of serial breast MRI tumor volumes in response to treatment and compares results to established in-house software. CADstreamTM produced similar results to those reported previously using in-house software (correlation coefficients ranged from 0.71 to 0.95, p<0.0003 for all visits). The reproducibility of results using commercially-available software supports the robustness of volumetric measurements of tumor response as a surrogate endpoint for survival outcomes.